Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort

Authors: Alexandre Lafourcade, Mathilde His, Laura Baglietto, Marie-Christine Boutron-Ruault, Laure Dossus, Virginie Rondeau

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

In addition to tumor characteristics and lifestyle factors, cancer relapses are often related to the risk of death but have not been jointly studied. We investigate the prognostic factors of recurrent events and death after a diagnosis of breast cancer and predict individual deaths including a history of recurrences.

Methods

The E3N (Etude Epidémiologique auprès de Femmes de la Mutuelle Générale de l’Education Nationale) study is a prospective cohort study that was initiated in 1990 to investigate factors associated with the most common types of cancer. Overall survival and three types of recurrent events were considered: locoregional recurrence, metastasis, and second primary breast cancer. Recurrent events and death were analyzed using a joint frailty model.

Results

The analysis included 4926 women from the E3N cohort diagnosed with a first primary invasive breast cancer between June 1990 and June 2008; during the follow-up, 1334 cases had a recurrence (median time of follow-up is 7.2 years) and 469 women died. Cases with high grade, large tumor size, axillary nodal involvement, and negative estrogen and progesterone receptors had a higher risk of recurrence or death. Furthermore, smoking increased the risk of relapse. For cases with a medium risk profile in terms of tumor characteristics and lifestyle factors, the probability of dying between 5 and 10 years after diagnosis was 6, 20 and 36% for 0, 1 or 2 recurrences within the first 5 years after diagnosis, respectively.

Conclusions

Our study showed the importance of considering baseline lifestyle characteristics and history of relapses to dynamically predict the risk of death in breast cancer cases. Medical experience coupled with an estimate of a patient’s survival probability that considers all available information for this patient would enable physicians to make better informed decisions regarding their actions and thus improve clinical output.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359.CrossRefPubMed
2.
go back to reference Lowery A, Kell M, Glynn R. Locoregional recurrence after breast cancer surgery : a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133(3):831–41.CrossRefPubMed Lowery A, Kell M, Glynn R. Locoregional recurrence after breast cancer surgery : a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133(3):831–41.CrossRefPubMed
3.
go back to reference Neri A, Marrelli D, Rossi S. Breast cancer local Recurrence : risk factors and prognostic relevance of early time to recurrence. World J Surg. 2007;31(1):36–45.CrossRefPubMed Neri A, Marrelli D, Rossi S. Breast cancer local Recurrence : risk factors and prognostic relevance of early time to recurrence. World J Surg. 2007;31(1):36–45.CrossRefPubMed
4.
go back to reference Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19(6):1688–97.CrossRefPubMed Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19(6):1688–97.CrossRefPubMed
5.
go back to reference Soerjomataram I, Louwman MWJ, Ribot JG, et al. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107(3):309–30.CrossRefPubMed Soerjomataram I, Louwman MWJ, Ribot JG, et al. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107(3):309–30.CrossRefPubMed
6.
go back to reference Assi HA, Khoury KE, Dbouk H, et al. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5(Suppl 1):S2.PubMedPubMedCentral Assi HA, Khoury KE, Dbouk H, et al. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5(Suppl 1):S2.PubMedPubMedCentral
7.
go back to reference Contiero P, Berrino F, Tagliabue G, et al. Fasting blood glucose and long-term prognosis of non-metastatic breast cancer : a cohort study. Breast Cancer Res Treat. 2013;138(3):951–9.CrossRefPubMedPubMedCentral Contiero P, Berrino F, Tagliabue G, et al. Fasting blood glucose and long-term prognosis of non-metastatic breast cancer : a cohort study. Breast Cancer Res Treat. 2013;138(3):951–9.CrossRefPubMedPubMedCentral
8.
go back to reference Dossus L, Boutron-Ruault M-C, Kaaks R, et al. Active and passive cigarette smoking and breast cancer risk: results from the EPIC cohort. Int J Cancer. 2014;134(8):1871–88.CrossRefPubMed Dossus L, Boutron-Ruault M-C, Kaaks R, et al. Active and passive cigarette smoking and breast cancer risk: results from the EPIC cohort. Int J Cancer. 2014;134(8):1871–88.CrossRefPubMed
9.
go back to reference Pierce J, Patterson RE, Senger CM, et al. Lifetime cigarette smoking and breast cancer prognosis in the after breast cancer pooling project. JNCI. 2013;106(1):djt359.CrossRefPubMedPubMedCentral Pierce J, Patterson RE, Senger CM, et al. Lifetime cigarette smoking and breast cancer prognosis in the after breast cancer pooling project. JNCI. 2013;106(1):djt359.CrossRefPubMedPubMedCentral
11.
go back to reference Holm M, Olsen A, Christensen J. Pre-diagnostic alcohol consumption and breast cancer recurrence and mortality : results from a prospective cohort with a wide range of variation in alcohol intake. Int J Cancer. 2013;132(3):686–94.CrossRefPubMed Holm M, Olsen A, Christensen J. Pre-diagnostic alcohol consumption and breast cancer recurrence and mortality : results from a prospective cohort with a wide range of variation in alcohol intake. Int J Cancer. 2013;132(3):686–94.CrossRefPubMed
12.
go back to reference Kwan ML, Kushi LH, Weltzien E, et al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast Cancer : the life after cancer epidemiology study. J Clin Oncol. 2010;28(29):4410–6.CrossRefPubMedPubMedCentral Kwan ML, Kushi LH, Weltzien E, et al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast Cancer : the life after cancer epidemiology study. J Clin Oncol. 2010;28(29):4410–6.CrossRefPubMedPubMedCentral
13.
go back to reference Newcomb PA, Kampman E, Trentham-dietz A, et al. Alcohol consumption before and after breast cancer Diagnosis : associations with survival from breast cancer, cardiovascular disease, and other causes. J Clin Oncol. 2013;31(16):1939–46.CrossRefPubMedPubMedCentral Newcomb PA, Kampman E, Trentham-dietz A, et al. Alcohol consumption before and after breast cancer Diagnosis : associations with survival from breast cancer, cardiovascular disease, and other causes. J Clin Oncol. 2013;31(16):1939–46.CrossRefPubMedPubMedCentral
14.
go back to reference Obi N, Heinz J, Seibold P, et al. Relationship between menopausal hormone therapy and mortality after breast cancer the MARIEplus study, a prospective case cohort. Int J Cancer. 2016;138(9):2098–108.CrossRefPubMed Obi N, Heinz J, Seibold P, et al. Relationship between menopausal hormone therapy and mortality after breast cancer the MARIEplus study, a prospective case cohort. Int J Cancer. 2016;138(9):2098–108.CrossRefPubMed
15.
go back to reference Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the women’s health initiative observational study. J Natl Cancer Inst. 2013;105(8):526–35.CrossRefPubMedPubMedCentral Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the women’s health initiative observational study. J Natl Cancer Inst. 2013;105(8):526–35.CrossRefPubMedPubMedCentral
16.
go back to reference Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Stat. Anal. Fail. Time Data, Second Ed. 2002;95–147. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Stat. Anal. Fail. Time Data, Second Ed. 2002;95–147.
17.
go back to reference Mauguen A, Rachet B, Mathoulin-Pélissier S, et al. Dynamic prediction of risk of death using history of cancer recurrences in joint frailty models. Stat Med. 2013;32(30):5366–80.CrossRefPubMed Mauguen A, Rachet B, Mathoulin-Pélissier S, et al. Dynamic prediction of risk of death using history of cancer recurrences in joint frailty models. Stat Med. 2013;32(30):5366–80.CrossRefPubMed
18.
go back to reference Rondeau V, Mathoulin-Pelissier S, Jacqmin-Gadda H, et al. Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events. Biostatistics. 2007;8(4):708–21.CrossRefPubMed Rondeau V, Mathoulin-Pelissier S, Jacqmin-Gadda H, et al. Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events. Biostatistics. 2007;8(4):708–21.CrossRefPubMed
21.
go back to reference Rondeau V, Mazroui Y, Gonzalez JR. FRAILTYPACK: an R package for the analysis of correlated data with frailty models using the penalized likelihood estimation. J Stat Softw. 2012;47(4):1–28.CrossRef Rondeau V, Mazroui Y, Gonzalez JR. FRAILTYPACK: an R package for the analysis of correlated data with frailty models using the penalized likelihood estimation. J Stat Softw. 2012;47(4):1–28.CrossRef
22.
go back to reference A. Krol, A. Mauguen, Y. Mazroui, A. Laurent, S. Michiels, and V. Rondeau. Tutorial in joint modeling and prediction : A statistical software for correlated longitudinal outcomes, recurrent events and a terminal event. J Stat Softw. 2017;81(3). A. Krol, A. Mauguen, Y. Mazroui, A. Laurent, S. Michiels, and V. Rondeau. Tutorial in joint modeling and prediction : A statistical software for correlated longitudinal outcomes, recurrent events and a terminal event. J Stat Softw. 2017;81(3).
23.
go back to reference Dunnwald LK, Rossing MA, Li CI. Research article hormone receptor status, tumor characteristics, and prognosis : a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9(1):1–10.CrossRef Dunnwald LK, Rossing MA, Li CI. Research article hormone receptor status, tumor characteristics, and prognosis : a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9(1):1–10.CrossRef
24.
go back to reference Antoine C, Liebens F, Carly B, et al. Influence of HRT on prognostic factors for breast cancer : a systematic review after the women ’ s health initiative trial. Hum Reprod. 2004;19(3):741–56.CrossRefPubMed Antoine C, Liebens F, Carly B, et al. Influence of HRT on prognostic factors for breast cancer : a systematic review after the women ’ s health initiative trial. Hum Reprod. 2004;19(3):741–56.CrossRefPubMed
25.
go back to reference Ravdin PM, Siminoff L, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19(4):980–91.CrossRefPubMed Ravdin PM, Siminoff L, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19(4):980–91.CrossRefPubMed
26.
go back to reference Krol A, Pignon J, Ducreux M, et al. Joint model for left-censored longitudinal data, recurrent events and terminal Event : predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000 – 05 trial. Biometrics. 2016;72(3):907–16.CrossRefPubMed Krol A, Pignon J, Ducreux M, et al. Joint model for left-censored longitudinal data, recurrent events and terminal Event : predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000 – 05 trial. Biometrics. 2016;72(3):907–16.CrossRefPubMed
Metadata
Title
Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort
Authors
Alexandre Lafourcade
Mathilde His
Laura Baglietto
Marie-Christine Boutron-Ruault
Laure Dossus
Virginie Rondeau
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4076-4

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine